Evidence map›Paper›PMID 38318827›Full record

ReviewMini reviews in medicinal chemistry2024

The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex

Sina Motamedy, Bahareh Soltani, Halimeh Kameshki, Asmae Alipour Kermani, Reza Saboori Amleshi, Masoud Nazeri, Mohammad Shabani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sina MotamedyNeuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
Bahareh SoltaniAfzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
Halimeh KameshkiAfzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
Asmae Alipour KermaniFaculty of Veterinary Medicine, Shahid Bahonar University, Kerman, Iran
Reza Saboori AmleshiNeuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
Masoud NazeriDepartment of Anesthesiology, Friedrich-Alexander-University Erlangen-Nuremberg, University Hospital Erlangen, Krankenhausstraße 12, 91054 Erlangen, Germany
Mohammad ShabaniNeuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, IranORCID 0000-0002-2082-5849

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sativex is a cannabis-based medicine that comes in the form of an oromucosal spray. It contains equal amounts of Δ9-tetrahydrocannabinol and cannabidiol, two compounds derived from cannabis plants. Sativex has been shown to have positive effects on symptoms of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and sleep disorders. It also has analgesic, antiinflammatory, antitumoral, and neuroprotective properties, which make it a potential treatment option for other neurological disorders. The article reviews the results of recent preclinical and clinical studies that support the therapeutic potential of Sativex and the molecular mechanisms behind its neuroprotective benefits in various neurological disorders. The article also discusses the possible advantages and disadvantages of using Sativex as a neurotherapeutic agent, such as its safety, efficacy, availability, and legal status.

Indexed as

CannabidiolDronabinolNeuroprotective AgentsPlant ExtractsAnimalsCannabisDrug CombinationsHumansMultiple SclerosisCannabidiolDronabinolDrug CombinationsnabiximolsNeuroprotective AgentsPlant Extractsamyotrophic lateral sclerosisantitumoralhuntington's disease.multiple sclerosisneuroprotectiveSativex

Identifiers

PMID38318827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.